The Use of Estrogens and Progestogens in Menopausal Hormone Therapy

doi:10.1017/9781108869102.019

Chapter 18 - The Use of Estrogens and Progestogens in Menopausal Hormone Therapy

Published online by Cambridge University Press: 18 June 2020

Kugajeevan Vigneswaran and

Edited by

Paula Briggs and

Nicholas Panay: Affiliation:
Queen Charlotte's & Chelsea Hospital, London
Paula Briggs: Affiliation:
Liverpool Women's NHS Foundation Trust
Gabor T. Kovacs: Affiliation:
Monash University, Victoria

Book contents

Get access

Summary

In November 1929, clinicians first attempted to develop an ‘ovary stimulating hormone’ extracted from the human placenta for the treatment of symptoms resulting from the menopause. The team at Montreal General Hospital named it ‘Emmenin’ and it had to be purified from the urine of pregnant women to be administered orally. It was later discovered that pregnant mares’ urine could provide an abundant supply of a compound with high estrogenic activity. This conjugated equine estrogen (CEE) was commercially produced as Premarin and made available as an oral estrogenic agent in 1939.

Information

Type: Chapter
Information: Managing the Menopause , pp. 177 - 186

DOI: https://doi.org/10.1017/9781108869102.019 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

National Institute for Health and Care Excellence. Menopause: diagnosis and management. NICE guideline [NG23]. November 2015.Google Scholar

International Menopause Society. IMS recommendations on women’s midlife health and menopause hormone therapy. 2016.Google Scholar

Hamoda, H, Panay, N, Arya, R, et al. British Menopause Society. The British Menopause Society and Women’s Health Concern 2016 recommendations on hormone replacement therapy in menopausal women. Post Reprod Health 2016;22(4):165–83.Google Scholar

Hamoda, H. British Menopause Society and Women’s Health Concern recommendations on the management of women with premature ovarian insufficiency.Google Scholar

North American Menopause Society. The 2017 hormone therapy position statement of he North American Menopause Society.Google Scholar

Accessibility standard: Unknown

Why this information is here

This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.

Accessibility Information

Accessibility compliance for the HTML of this chapter is currently unknown and may be updated in the future.